PUBLISHER: The Business Research Company | PRODUCT CODE: 1951746
PUBLISHER: The Business Research Company | PRODUCT CODE: 1951746
Effervescent and chewing tablets serve as oral dosage forms engineered for swift disintegration and uptake. Effervescent tablets break down in water, liberating carbon dioxide to form a bubbling solution that speeds up absorption. Chewing tablets, by contrast, get chewed prior to swallowing, promoting direct interaction with saliva for a quicker therapeutic effect.
The primary categories of effervescent and chewing tablets consist of effervescent tablets and chewing tablets. An effervescent tablet is a solid dosage form that disintegrates in water, producing carbon dioxide bubbles to create an effervescent drink, often employed for rapid medication delivery, vitamin intake, and electrolyte replenishment. These items reach consumers via multiple outlets, such as pharmacies and drugstores, supermarkets and hypermarkets, e-commerce platforms, and medical professionals. They serve a range of purposes, including medical treatments, dietary supplements, weight control, and personal care, with target users encompassing adults, kids, older adults, and sports enthusiasts.
Tariffs have affected the effervescent and chewing tablet market by increasing the cost of imported excipients, active pharmaceutical ingredients, and specialized packaging materials used in solid dosage manufacturing. These impacts are most evident among manufacturers in Asia Pacific and Europe that rely on cross border sourcing of formulation inputs. Rising tariff related costs have placed pressure on production margins and pricing strategies across consumer health and pharmaceutical segments. In some cases, this has influenced product reformulation and packaging optimization efforts. However, tariffs are also encouraging local sourcing of raw materials, domestic manufacturing expansion, and greater supply chain self reliance over time.
The effervescent and chewing tablet market research report is one of a series of new reports from The Business Research Company that provides effervescent and chewing tablet market statistics, including effervescent and chewing tablet industry global market size, regional shares, competitors with a effervescent and chewing tablet market share, detailed effervescent and chewing tablet market segments, market trends and opportunities, and any further data you may need to thrive in the effervescent and chewing tablet industry. This effervescent and chewing tablet market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The effervescent and chewing tablet market size has grown rapidly in recent years. It will grow from $4.88 billion in 2025 to $5.48 billion in 2026 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to growth in self-medication practices, increasing prevalence of vitamin deficiencies, rising demand for pediatric-friendly formulations, expansion of otc healthcare products, improved palatability of oral drugs.
The effervescent and chewing tablet market size is expected to see rapid growth in the next few years. It will grow to $8.74 billion in 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to growing health-conscious population, rising demand for sports and fitness supplements, innovation in flavor and formulation technologies, expansion of online healthcare retail, increasing focus on preventive nutrition. Major trends in the forecast period include growing preference for fast-absorbing oral dosage forms, rising demand for nutritional and vitamin supplements, increasing adoption of sugar-free chewing tablets, expansion of consumer-friendly drug delivery formats, higher use in preventive healthcare and wellness.
The increasing incidence of digestive disorders is anticipated to boost the effervescent and chewing tablet market in the years ahead. Digestive disorders encompass conditions impacting the gastrointestinal tract, such as indigestion, bloating, heartburn, and chronic inflammatory conditions. Their prevalence is on the rise due to poor diets, elevated stress, inactive lifestyles, and greater intake of processed foods. The effervescent and chewing tablet market aids digestive health by delivering quick, user-friendly relief from minor gastrointestinal issues. For instance, in September 2023, the IBD Clinical and Research Centre-a Canada-based non-profit-reported a prevalence of 825 cases per 100,000 people in Canada, affecting over 320,000 individuals with inflammatory bowel disease (IBD), with forecasts showing this number climbing to 470,000 by 2035. Thus, the growing prevalence of digestive disorders is fueling expansion in the effervescent and chewing tablet market.
Major companies in the effervescent and chewing tablet market are prioritizing innovative developments, like advanced nutrient blends and user-friendly delivery options, to improve consumer adherence and product performance. Advanced nutrient blends involve products with elevated or refined concentrations of vitamins, minerals, or other bioactive components for superior health outcomes, whereas user-friendly delivery options include accessible formats such as chewable or effervescent tablets that enhance usability and compliance. For example, in September 2023, Reckitt Benckiser Group plc, a UK-headquartered global consumer goods firm, introduced Airborne's most robust immune support formula, timed ideally for the back-to-school period. The updated effervescent and chewable supplements now incorporate seven key immune-boosting nutrients-Vitamin C, Vitamin D, Zinc, Vitamin A, Vitamin E, Manganese, and Selenium-with boosted Zinc content and the inclusion of Vitamin D. Crafted for fuller daily immune protection, the formula supplies at least 20% of the daily value for each nutrient. Offered in Zesty Orange, Very Berry, and Citrus varieties, the product is available at leading retailers like Walmart, Walgreens, Target, and CVS.
In November 2025, Nextpharma Holdings Ltd., a Norway-based pharmaceutical contract development and manufacturing company, purchased Takeda's advanced chewable tablet production facility in Asker for an undisclosed sum. Through this acquisition, NextPharma seeks to bolster its manufacturing capabilities and solidify its standing in the European oral dosage market. Takeda Pharmaceutical Company Limited, a Japan-based multinational pharmaceutical firm, focuses on developing and manufacturing a broad array of pharmaceutical products, including sophisticated chewable and oral tablet formulations.
Major companies operating in the effervescent and chewing tablet market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi SA, Abbott Laboratories, Teva Pharmaceutical Industries, Amway Corp., Sun Pharmaceutical Industries Ltd., Herbalife International Inc., Dr Reddy's Laboratories Ltd., Leo Nutriscience, Bliss GVS Pharma Limited, Tower Laboratories Ltd., Vitabiotics Ltd., Losan Pharma GmbH, Nutra Healthcare Private Limited, Vovantis Laboratories Pvt. Ltd., BHI Biohealth International GmbH, Nutrilo GmbH, PharmaEstica Manufacturing OU, The Himalayan Organics, The Vitamin Company
North America was the largest region in the effervescent and chewing tablet market in 2025. The regions covered in the effervescent and chewing tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the effervescent and chewing tablet market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The effervescent and chewing tablet market consists of sales of vitamin and mineral supplements, pain relief tablets, and gastrointestinal relief products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Effervescent And Chewing Tablet Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses effervescent and chewing tablet market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for effervescent and chewing tablet ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The effervescent and chewing tablet market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.